Draft Minutes of Pre-bid meeting for PROCUREMENT OF HIV RAPID TEST Kits against: IFB No. RITES/MSM/NACP/01/2017/Rebid held on 16.07.2018 at 14:30 hr at RITES office.

1. The following were present:-

I) From RITES
S/Shri
Chandan Kumar JGM/MSM– In Chair
Nitin Jain AM/MSM
Kumar Anuj, Engineer/MSM

II) Firms which attended the pre bid conference are as follows:

S. No.	Name of representative S/Shri	Name of Firm
1	Rajesh Verma	M/s Medsource Ozone Biomedicals Pvt. Ltd.

2. Initiating the discussion, chairperson welcomed the participants. It was explained that purpose of Pre-bid meet is to educate the bidders regarding various important provisions of the bidding documents and also to clarify any queries that the bidders may have in the subject bidding documents. All the prospective bidders were requested to get themselves registered with Central Public Procurement (CPP) portal (https://etenders.gov.in/eprocure/app) as early as possible.

3. The issues raised during the pre bid meeting and clarifications are as under-

S. No.	Query Raised	Clarification
	Section I: ITB Clause 19.3 (a):	
1.	As per Bid Document, Bank Guarantee towards Bid Security is to be submitted in favour of the Purchaser. As per Definition 1(g) in GCC Purchaser is. Ministry of Health & Family Welfare, Government of India through RITES LTD, New Delhi Kindly clarify in which name Bank guarantee has to be made. Kindly clarify.	**Refer Amendment No 4**
	Section IV: Technical Specifications	
2.	**PART 'A', 3 (By any other Principle excluding Agglutiation and Enzyme Immune Assay) Point No. 10** Firm has enquired that In Rapid Test "Lateral Flow (Immuno Chromatography Technology)" there is no provision of separate quoting of Antigens rather they are on the same strip (Control, HIV2 and HIV1 bands). Moreover separate pack sizes is required as per bid document which is again not possible, so it is proposed to delete this point or amend as "Quoting of Antigens for HIV 2 and HIV 1 are on same strip".	**Refer Amendment No 4**
3.	**PART 'A', Specification, Point No. 10** By any other Principle excluding Agglutination and Enzyme Immuno Assay - you have mentioned that **"for 2nd & 3rd Antigens : the pack size of HIV Rapid Test Kits should not be more than 20 Tests per kit".** In this regard, as per Schedule of Requirements, wherein Consignee Wise Distribution is in consideration to Tests per kit, so firm has requested to confirm whether the pack size of HIV Rapid Test Kits is not more than 30 Tests per kit instead of 20 Tests.	

4.	**Part C, Serial No. 4 under the Packing (Clause No. 10 of GCC):** As per Specification "**Packing List Reference Number"**, is required on each unit package. Firm has requested to amend the above clause as **"to put Packing List Reference Number on Tertiary Packing (Shipper/Outer Packing)"** instead of putting on the each unit package, as it is not feasible at the Unit Packaging.	**As per Bid Document.**
5.	**Page No. 13 Clause 6.1.1 (C):** As per Bid Document, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, firm has proposed to consider the manufacturing and marketing experience of Rapid test kits or diagnostic test kits for this clause."	**Not acceptable.**
6.	**Point No. 9** The control dot/band should be able to detect the presence of human immune globulins and should not be just a "procedural control" or meant for merely checking the flow or reagents or integrity of the antigen except in kits using "lateral flow (Immuno cyto flow) or flow through Immuno concentration)" technology. The firm has requested to confirm whether the above point is required/ valid in case of "Lateral Flow (Immuno Chromatography Technology)"	**Yes. This point is required for "Lateral Flow (Immuno Chromatography Technology)".**
7.	**Point No. 10 Sub-point No. 2** The assay components should include HIV positive and negative serum controls sufficient for conducting 20% of the tests (10% negative and 10% positive controls). The firm has proposed to delete this point as Negative and Positive Controls are been a part of ELISA Tests Principal and Not for Rapid Tests.	**Not acceptable.**
8.	**Point No. 12** The manufacturer/ authorized agent should ensure maintenance of cold chain during storage & transport the kits at 2-8°C. The cumulative time temperature indicator technology should be pre qualified by WHO. The firm has proposed that Usually all Rapid Tests are stable at Room Temperature and this indicator is not been required. No such " Time Temperature Technology is been pre-qualified by WHO" and requested you to amend it as "Kit Should be stable at Room Temperature".	**Not acceptable.**

Meeting concluded with thanks to the participant for their active participation.